Oncology (diet epidemiology) 2021

Mushroom consumption and cancer risk: systematic review and meta-analysis of 17 observational studies

The Ba et al. (Penn State) meta-analysis pooled 17 observational studies (MEDLINE, Web of Science, Cochrane; 1966–31 Oct 2020). Higher mushroom intake was associated with lower risk of any cancer (pooled RR highest vs lowest: 0.66; 95% CI 0.55–0.78; n=17), breast cancer (0.65; 0.52–0.81; n=10) and non-breast sites (0.80; 0.66–0.97; n=13), with a significant nonlinear dose-response (P=0.001; n=7). Eleven of 17 studies were case-control, exposed to recall and selection bias; adjustment sets varied widely.

Ba D.M., Ssentongo P., Beelman R.B., Muscat J., Gao X., Richie J.P. Higher Mushroom Consumption Is Associated with Lower Risk of Cancer: A Systematic Review and Meta-Analysis of Observational Studies. Advances in Nutrition. 2021;12(5):1691–1704.

Rationale

First meta-analysis asking whether eating mushrooms — not taking extracts — is associated with cancer incidence in human studies.

Methods

Observational studies reporting RR/HR/OR for ≥2 categories of mushroom intake, searched 1966–Oct 2020; random-effects pooling plus nonlinear dose-response. 17 studies: 11 case-control, 6 cohorts.

Results

  • Any cancer: pooled RR 0.66 (95% CI 0.55–0.78), n=17.
  • Breast cancer: 0.65 (0.52–0.81), n=10; non-breast: 0.80 (0.66–0.97), n=13.
  • Significant nonlinear dose-response (P=0.001) — the curve drops steeply at low intake and plateaus: the first weekly serving contributes more than the fifth.

Conclusions

Higher mushroom consumption is associated with lower cancer risk — most robustly breast cancer — consistent with a dietary protective role, pending prospective and interventional confirmation.

Worth noting

This is epidemiology of diet, not therapy: 11/17 studies are case-control, where patients recall diet differently after diagnosis — the 0.66 figure is best read as an upper bound of a possible effect, not proof. The nonlinear plateau is the interesting part: modest regular intake saturates the association, which fits an ergothioneine-type "enough is enough" hypothesis rather than "more is better."